2.24
Goodrx Holdings Inc stock is traded at $2.24, with a volume of 1.35M.
It is up +1.36% in the last 24 hours and up +2.75% over the past month.
GoodRx Holdings Inc is a consumer-focused digital healthcare platform that aims to lower the cost of healthcare in the United States. It operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and provides access to negotiated prices through codes that can be used to save money on prescriptions across the United States. GoodRx generates revenue from core business from pharmacy benefit managers (PBMs) that manage formularies and prescription transactions including establishing pricing between consumers and pharmacies. It also offers various healthcare products and services, including pharma manufacturer solutions, subscriptions, and telehealth services.
See More
Previous Close:
$2.21
Open:
$2.2
24h Volume:
1.35M
Relative Volume:
0.45
Market Cap:
$767.37M
Revenue:
$796.85M
Net Income/Loss:
$30.44M
P/E Ratio:
26.60
EPS:
0.0842
Net Cash Flow:
$93.88M
1W Performance:
-1.75%
1M Performance:
+2.75%
6M Performance:
-46.54%
1Y Performance:
-49.89%
Goodrx Holdings Inc Stock (GDRX) Company Profile
Name
Goodrx Holdings Inc
Sector
Industry
Phone
(855) 268-2822
Address
2701 OLYMPIC BOULEVARD, SANTA MONICA
Compare GDRX vs VEEV, TEM, BTSG, HQY, WAY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
GDRX
Goodrx Holdings Inc
|
2.24 | 757.09M | 796.85M | 30.44M | 93.88M | 0.0842 |
|
VEEV
Veeva Systems Inc
|
178.88 | 29.72B | 3.20B | 908.91M | 1.42B | 5.4155 |
|
TEM
Tempus Ai Inc
|
49.98 | 8.85B | 1.27B | -245.03M | -245.36M | -1.4071 |
|
BTSG
Brightspring Health Services Inc
|
38.31 | 7.42B | 12.91B | 104.80M | 394.69M | 0.8769 |
|
HQY
Healthequity Inc
|
77.81 | 6.56B | 1.15B | 96.70M | -161.99M | 1.09 |
|
WAY
Waystar Holding Corp
|
24.16 | 4.72B | 1.10B | 112.09M | 283.19M | 0.6096 |
Goodrx Holdings Inc Stock (GDRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-27-26 | Downgrade | JP Morgan | Overweight → Neutral |
| Jan-22-26 | Downgrade | Jefferies | Buy → Hold |
| Dec-09-25 | Initiated | Barclays | Underweight |
| Aug-11-25 | Downgrade | Raymond James | Strong Buy → Outperform |
| Dec-04-24 | Initiated | Mizuho | Neutral |
| Aug-09-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| May-23-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| May-16-24 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Apr-10-24 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Mar-25-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-01-24 | Upgrade | JP Morgan | Neutral → Overweight |
| Feb-26-24 | Initiated | Leerink Partners | Outperform |
| Jan-02-24 | Downgrade | BofA Securities | Buy → Underperform |
| Aug-10-23 | Upgrade | DA Davidson | Neutral → Buy |
| Jul-31-23 | Upgrade | TD Cowen | Market Perform → Outperform |
| Dec-01-22 | Initiated | Citigroup | Buy |
| Nov-04-22 | Upgrade | JP Morgan | Underweight → Neutral |
| Sep-16-22 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Sep-07-22 | Initiated | Truist | Hold |
| Aug-12-22 | Initiated | DA Davidson | Neutral |
| Jun-10-22 | Downgrade | Goldman | Buy → Neutral |
| Jun-06-22 | Resumed | BofA Securities | Buy |
| Jun-01-22 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-10-22 | Downgrade | Evercore ISI | Outperform → In-line |
| May-10-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| May-10-22 | Downgrade | Raymond James | Outperform → Mkt Perform |
| May-10-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Apr-11-22 | Initiated | Wells Fargo | Equal Weight |
| Apr-07-22 | Initiated | Guggenheim | Buy |
| Apr-01-22 | Resumed | Credit Suisse | Neutral |
| Mar-15-22 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Mar-01-22 | Reiterated | Barclays | Overweight |
| Mar-01-22 | Reiterated | BofA Securities | Neutral |
| Mar-01-22 | Downgrade | Cowen | Outperform → Market Perform |
| Mar-01-22 | Downgrade | Credit Suisse | Outperform → Neutral |
| Mar-01-22 | Reiterated | Evercore ISI | Outperform |
| Mar-01-22 | Reiterated | Goldman | Buy |
| Mar-01-22 | Reiterated | JP Morgan | Underweight |
| Mar-01-22 | Reiterated | RBC Capital Mkts | Outperform |
| Mar-01-22 | Reiterated | SVB Leerink | Outperform |
| Jan-07-22 | Initiated | Goldman | Buy |
| Dec-21-21 | Initiated | Stephens | Overweight |
| Dec-02-21 | Initiated | Jefferies | Buy |
| Aug-31-21 | Upgrade | Barclays | Equal Weight → Overweight |
| Aug-13-21 | Upgrade | Raymond James | Mkt Perform → Outperform |
| May-28-21 | Initiated | Robert W. Baird | Neutral |
| Apr-06-21 | Resumed | Evercore ISI | Outperform |
| Jan-25-21 | Initiated | Guggenheim | Buy |
| Nov-19-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-18-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-19-20 | Initiated | Barclays | Equal Weight |
| Oct-19-20 | Initiated | BofA Securities | Neutral |
| Oct-19-20 | Initiated | Citigroup | Buy |
| Oct-19-20 | Initiated | Cowen | Outperform |
| Oct-19-20 | Initiated | Credit Suisse | Outperform |
| Oct-19-20 | Initiated | Deutsche Bank | Hold |
| Oct-19-20 | Initiated | Goldman | Neutral |
| Oct-19-20 | Initiated | JP Morgan | Neutral |
| Oct-19-20 | Initiated | Morgan Stanley | Overweight |
| Oct-19-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Oct-19-20 | Initiated | SVB Leerink | Outperform |
| Oct-19-20 | Initiated | UBS | Buy |
View All
Goodrx Holdings Inc Stock (GDRX) Latest News
Published on: 2026-03-12 03:47:43 - baoquankhu1.vn
GoodRx (NASDAQ:GDRX) Shares Down 6%Time to Sell? - MarketBeat
GoodRx Holdings, Inc. announced that consumers paying with cash through its platform can enjoy up to 85% discounts on medications at more than 70,000 pharmacies across the United States. - Bitget
GoodRx (GDRX) Partners with Viatris for Major Medication Discoun - GuruFocus
GoodRx offers up to 85% discount on Viatris drugs (GDRX) - Seeking Alpha
Lipitor and Viagra discounts: GoodRx deal cuts brand drugs to $0–$4 - Stock Titan
GoodRx (GDRX) CAO converts RSUs to stock and withholds shares for taxes - Stock Titan
GoodRx: Losing Relevance With Consumers (Downgrade) (NASDAQ:GDRX) - Seeking Alpha
GoodRx (GDRX) Q4 2025 Earnings Call Transcript - AOL.com
Aug Technicals: How does GoodRx Holdings Inc perform in inflationary periods2025 Investor Takeaways & Verified Momentum Stock Ideas - baoquankhu1.vn
Aug Reactions: Is GoodRx Holdings Inc showing insider buyingMarket Movement Recap & Short-Term High Return Ideas - baoquankhu1.vn
GoodRx awards discretionary cash bonus to chief accounting officer - Investing.com UK
GoodRx awards discretionary cash bonus to chief accounting officer By Investing.com - Investing.com South Africa
GoodRx Awards Performance-Based Bonus to Chief Accounting Officer - TipRanks
GoodRx (GDRX) Board approves $72,918 bonus for Chief Accounting Officer - Stock Titan
U.S. medical discount service provider GoodRx Holdings, Inc. recently announced the launch of an innovative subsidy program for self-insured employers. - Bitget
GoodRx to expand employer-sponsored access to Zepbound® Kwikpen® - marketscreener.com
Obesity drug Zepbound now offered to workers at $449 through GoodRx - Stock Titan
GDRX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
GDRX: Wells Fargo Maintains Rating, Lowers Price Target by 50% | - GuruFocus
Wells Fargo & Company Has Lowered Expectations for GoodRx (NASDAQ:GDRX) Stock Price - MarketBeat
GoodRx Holdings (GDRX) Analyst Rating Update: Citigroup Lowers P - GuruFocus
Citigroup Lowers GoodRx (NASDAQ:GDRX) Price Target to $3.50 - MarketBeat
GoodRx Holdings, Inc. (GDRX) Stock Analysis: A 51.74% Upside Potential Awaits Investors - DirectorsTalk Interviews
GDRX Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
GoodRx (NASDAQ:GDRX) Trading Up 9.4%Should You Buy? - MarketBeat
The Goldman Sachs Group Lowers GoodRx (NASDAQ:GDRX) Price Target to $2.50 - MarketBeat
Goldman Sachs Lowers GoodRx Holdings (GDRX) Price Target to $2.5 - GuruFocus
GoodRx Earnings Call Marks Transitional Reset Year - TipRanks
GoodRx Announces Resignation of Board Member Dipanjan Deb - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: GoodRx Holdings (GDRX) and Vericel (VCEL) - The Globe and Mail
Assessing GoodRx Holdings (GDRX) Valuation After Employer Direct Launch And Post Earnings Analyst Shifts - simplywall.st
Why GoodRx (GDRX) Is Down 19.4% After Unveiling Employer Direct And 2026 Revenue Guidance - Yahoo Finance
GoodRx (GDRX) board member Dipanjan Deb steps down without dispute - Stock Titan
GoodRx Holdings, Inc.Class A Common Stock (NQ: GDRX - The Chronicle-Journal
GoodRx Holdings (GDRX) Analyst Rating and Price Target Update | - GuruFocus
GoodRx (NASDAQ:GDRX) Given New $3.00 Price Target at Mizuho - MarketBeat
Hims & Hers Expands Digital Health and Global Platform Strategy - TradingView
GoodRx 2026 Guidance Signals Material Reset, Morgan Stanley Says - marketscreener.com
UBS Lowers Price Target on GoodRx Holdings to $2 From $4, Maintains Neutral Rating - marketscreener.com
Raymond James cuts GoodRx stock price target on pharma headwinds By Investing.com - Investing.com Nigeria
Raymond James cuts GoodRx stock price target on pharma headwinds - Investing.com
JPMorgan Chase & Co. Reaffirms Neutral Rating for GoodRx (NASDAQ:GDRX) - MarketBeat
A Glimpse Into The Expert Outlook On GoodRx Holdings Through 4 Analysts - Benzinga
GoodRx Holdings (GDRX) Downgraded by JP Morgan to Neutral | GDRX Stock News - GuruFocus
JPMorgan Downgrades GoodRx to Neutral From Overweight - marketscreener.com
Morgan Stanley Cuts Price Target on GoodRx Holdings to $3 From $4, Keeps Equalweight Rating - marketscreener.com
GDRX: GoodRx drives ~$17B in annual consumer savings and achieves profitable growth with expanding partnerships - TradingView
GoodRx Holdings GDRX Margin Improvement Reinforces Bullish Profitability Narratives - simplywall.st
GoodRx Q4 2025 Earnings: Revenue Down, Future Guidance Below EstimatesNews and Statistics - IndexBox
GoodRx Holdings, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Goodrx Holdings Inc Stock (GDRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):